Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800092 · ClinicalTrials.gov registry record · Phase 2
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT06800092 is a Phase 2 study that has not yet begun recruiting, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 30 participants.
The verdict
NCT06800092, a Phase 2 study, has not yet begun recruiting, sponsored by The University of Texas Medical Branch, Galveston.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
Interventions
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2027-06-15 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06800092
The ClinicalTrials.gov registry entry for NCT06800092 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil is the first listed.
NCT06800092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06800092 about?
NCT06800092 is a clinical study titled "Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment". This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
What is the current status of trial NCT06800092?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2027-06-15. Estimated completion is 2030-06-01.
What interventions are being tested in trial NCT06800092?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT06800092?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.